(r)terazosin

(R)-Terazosin is an active R-enantiomer of Terazosin and a potent antagonist of α1-adrenoceptor [(α1a, α1b, and α1d-adrenoceptor] with Ki values of 6.51 nM, 1.01 nM, and 1.97 nM, respectively).

Terazosin, a quinazoline derivative, is an orally active and competitive antagonist of α1-adrenoceptors. Its mechanism of action involves relaxing blood vessels and promoting bladder opening. Terazosin exhibits therapeutic potential for treating benign prostatic hyperplasia (BPH) and high blood pressure [1][2][3].

Terazosin hydrochloride (Hytrin) , a selective alpha1-antagonist, can treat the benign prostatic hyperplasia (BPH). It also can lower blood pressure, so it is a drug of choice for patients with prostate enlargement and hypertension. It works on the smooth muscle of the bladder and the blood vessel walls by blocking the function of adrenaline.

Terazosin-d8 is a deuterated compound of Terazosin. Terazosin has a CAS number of 63590-64-7. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment [1] [2] [3].

(S)-Terazosin is an active S-enantiomer of Terazosin and acts as a potent, high-affinity antagonist of α-adrenoceptors [α1a, α1b, and α1d-adrenoceptors] with Ki values of 3.91 nM, 0.79 nM, and 1.16 nM, respectively.

Terazosin hydrochloride dihydrate (Heitrin dihydrate) is a selective α1-adrenoceptor antagonist, used for treatment of symptoms of an enlarged prostate (BPH).